NIPC Law

  Kidney Stone Author  Robert R Wal  Licence  Public Domain       Jane Lambert Intellectual Property Enterprise Court (HH Judge Hacon) Well Lead Medical Co Ltd v CJ Medical Ltd [2025] EWHC 492 (IPEC) (7 March 2025) This was an action by Well Lead Medical Co Ltd. ("Well Lead") against CJ Medical Ltd ("CJ Medical") for the infringement of EP (UK) 3 760 143 B1 and a counterclaim by CJ Medical for the revocation of that patent under s.72 (1) (a) and (d) of the Patents Act 1977. The action and counterclaim were trued by His Honour Judge Hacon on 3 and 4 Feb 2025.  His Honour handed down judgment on 7 March 2025 (see Well Lead Medical Co Ltd v CJ Medical Ltd [2025] EWHC 492 (IPEC) (7 March 2025)).  By para [150] of his judgment, the learned judge held that claim 3 was valid and infringed but claim 1 was invalid for obviousness. Interim Injunctive Proceedings I have previously discussed Charlotte May KC's judgment in Well Lead Medical Co Lt...

Shell Petrol Station Author Ianmcm   Public Domain Courtesy of the author   Soutce Wikimedia Commons Jane Lambert Court of Appeal (Lords Justices Phillips and Birss and Lady Justice Whipple)  Ensygnia IP Ltd v Shell UK Oil Products Ltd and others [2024] EWCA Civ 1490 (5 Dec 2024) This was an appeal against the judgment of Miss Charlotte May KC sitting as a deputy judge of the High Court in  Ensygnia IP Ltd v Shell Oil Products Ltd and others [2023] EWHC 1495 (Pat) of 26 June 2023.  That had been a claim by Ensygnia IP Ltd. ("Ensygnia") against Shell Oil Products Ltd, Shell International Petroleum Ltd. and Shell Information Technology BV ("Shell") for the alleged infringement of UK patent  GB 2,489,332 C2  and a counterclaim by Shell for revocation of the patent.  In para [300] of her judgment, Miss May held that the patent was invalid for added matter, extension of scope, and obviousness.  However, she also stated that the patent woul...

Autho r Brenton Licence CC BY-SA 4.0 Source Wikimedia Commons Jane Lambert Patents Cour t (HH Judge Hacon) S andoz AG and others v Bayer Intellectual Property GmbH [2024] EWHC 796 (Pat) (12 April 2024 ) These were conjoined actions by several generic pharmaceutical manufacturers against Bayer Intellectual Property GmbH ("Bayer") for the revocation of European patent (UK) 1 845 961 ("the Patent") for the treatment of thromboembolic disorders with rivaroxaban . There were also counterclaims by Bayer for injunctions to restrain the threatened infringement of the Patent. Those threats were conceded for the purposes of the trial. Consequently, the validity of the Patent was the only issue to be tried. His Honour Judge Hacon tried those actions on 9, 12, 13,14, 15 and 16 Jan and 21 and 22 Feb 2024. By para [272] of his judgment in Sandoz AG and others v Bayer Intellectual Property GmbH [2024] EWHC 796 (Pat) handed down on 12 April 2024, the learned judge found t...